glp-1 weight loss drug news today 2025 Alarming rise in overdoses Americans turn to risky unregulated
Description
What's the peptide class after triple agonist
Gromada J, Franklin I, Wollheim CB
95% CI 0.160.33) compared with the non-GLP-1 RAs group
This initially seemed problematic for a weight loss medication
Once consequence of obesity fatty liver disease showed normalization of liver fat in 9/10 people on one of the new GLP-1 medicines
